Editas Medicine (EDIT) investor relations material

Company overview and business model

• Pioneering gene editing company focused on developing transformative genomic medicines using a proprietary CRISPR platform.

• Product strategy targets diseases where gene editing can enable or enhance therapeutic outcomes, with a focus on in vivo gene editing and functional upregulation.

• Lead candidate EDIT-401 aims to treat hyperlipidemia by upregulating LDL receptor expression to reduce LDL cholesterol.

• Preclinical efforts include a lipid nanoparticle platform for targeted delivery to various tissues, including liver and hematopoietic stem cells.

Financial performance and metrics

• As of July 31, 2026, 153,580,035 shares of common stock were outstanding; no preferred stock was outstanding.

• Net tangible book value as of June 30, 2026, was $0.69 per share; after the offering, as adjusted, $1.25 per share.

• Immediate dilution to new investors in the offering is estimated at $1.91 per share.

Use of proceeds and capital allocation

• Net proceeds from securities sales will be used for general corporate purposes, including R&D, acquisitions, debt repayment, working capital, and capital expenditures.

• For the $150 million ATM offering, proceeds are intended for EDIT-401 clinical development, manufacturing, R&D, working capital, and potential business development opportunities.

• Management retains broad discretion over allocation of proceeds.